✕
☰

“PERFECTing” the pharma packaging selection process

by

Gabrielle Gehron, scientific support manager, Datwyler, explains how to successfully analyse your pharma packaging needs and navigate through the packaging selection process.

Key insights:

With reverberations from the recent pandemic still in play, drug manufacturers continue to search for high-quality packaging products for their pharmaceuticals. Additionally, regulations are becoming increasingly strict in the name of patient safety.

It is of the utmost concern to mitigate risks associated with those components which protect and package sensitive drug formulations. This collection of challenges is driving drug makers to search for ways to find the highest-quality, most compatible components as quickly as possible. Fortunately, companies can implement a simple checklist to successfully analyse their packaging needs and navigate through the packaging selection process.

“PERFECT” packaging systems

To “perfect” or more accurately speaking, improve a packaging system, it is critical to keep in mind the most important aspects of component selection:

(P) Particles

Particles can include any foreign substances, such as fibre or dirt, that could enter the product by way of the packaging component. By washing and sterilising all parenteral drug components, companies can greatly reduce the possibility of particulate entering the drug. Companies such as Datwyler specialise in washing and sterilising rubber components that are then sold to companies ready for use, which decreases their customers’ total cost of ownership (TCO) and time spent on preparing components for filling.

Drug manufacturers will want to assess their own needs and capabilities and select compatible products. For example, a manufacturer with sterilisation capabilities may be able to purchase RfS (Ready for Sterilisation – washed, but not sterilised) products, while as a company without these capabilities may prefer RTU (Ready to Use – washed and sterilised) products.

(E) Extractables & Leachables

Extractables and leachables are chemicals within a packaging component that could be pulled out by the contained drug product. They also include chemicals that may be formed via reactions between the packaging and drug product. Suppliers ought to provide to their customers lists of substances that could potentially be extracted from a given product. Customers may then be able to evaluate which leachables could be problematic based on what drug is being packaged. Drug manufacturers benefit from having potential extractables information up front so they can make an informed decision on components that may react poorly with their drug product.

(R) Regulations

Regulations must be monitored to ensure that products align with patient safety standards. However, this must be done with respect to the region in which a drug will be marketed. For example, in China, pharmaceutical companies are still adjusting to matters concerning the Bundling Review implemented in 2016 by the China Food and Drug Administration (CFDA) (comparable to the Food and Drug Administration (FDA) system in the United States). Prior to this, there was a less-strict licensing system for packaging materials in this region.

In addition to parenteral drug manufacturers maintaining alignment with regulations, suppliers must also comply with these regulations, and they can support their customers by providing parts that will be compatible with those regulations. By choosing a supplier who aligns with and prioritises core regulations, drug manufacturers can be assured their products will follow the highest standards required.

(F) Functionality

Functionality refers to how a drug manufacturer’s components interact with other pieces of their system. When purchasing a component for the first time, drug manufacturers must take time to test all components simultaneously to ensure a fully functioning system. Some functionality requirements for elastomer products may include:

(E) Engineering Capabilities

“Engineering capabilities” (similar to manufacturability) refers to how components move on a fill/finish line. For example, a component that is under-lubricated may stick to machining lines, resulting in a cessation of fill/finish until operators can resolve the issue. However, over-lubrication can result in excess residue on lines and in the end-product, creating unnecessary particulate.

To ensure components will run successfully at a drug manufacturer’s plant, newly purchased components must go through Factory Acceptance Testing (FAT) and Site Acceptance Testing (SAT.) While FAT requires the supplier to run a product through testing at the site where a filling machine is made, SAT requires testing at the drug manufacturer’s final filling site. Both tests aim to mitigate problems on the final fill line at a drug manufacturer’s site and address potential issues well before that stage. Companies who have established fill/finish lines may prefer to use components that will require only minor adjustments to their lines, when possible, across all of their projects.

(C) Container Closure Integrity

Container closure integrity (CCI) is the ability for all components to fit together properly and seal fully, preventing the transfer of any substances into or out of the system. CCI can be evaluated theoretically prior to committing to a product; this is done by calculating the interference between the rubber component and its (typically glass or plastic) container, and (for vial systems) by calculating the theoretical overhang length of a seal used to cap a vial and stopper. Experimentally, many forms of testing exist to evaluate the CCI of a system, including Helium Leak and Dye Ingress. If CCI is not verified, drug products could become contaminated, adversely effecting patient outcomes and risking consumer confidence.

(T) Total Quality

Quality is a critical aspect of ensuring that a product meets the standards required by both regulatory bodies and internal business guidelines. Many companies have entire departments dedicated to setting and maintaining quality standards, and to ensuring that their suppliers do the same.

Potential areas to prioritise may include:

Conclusion

In an environment awash with complications from the COVID-19 pandemic, increasing regulations, and higher quality standards, the pharmaceutical industry must continue to serve patients and caregivers. When drug manufacturers are better able to understand and evaluate their packaging components, they gain agency and confidence in their decisions. ”PERFECTing” the packaging selection process can be made easier by beginning with a dedicated checklist and partnering with reputable suppliers. By implementing these measures, pharmaceutical companies can achieve increased success and overcome whatever challenges still lie ahead.

Back to topbutton